JG Summit Holdings (OTC:JGSMY) Stock, Quote.Headers.trade-ideas

JG Summit Holdings Inc is a diversified Filipino conglomerate, engaged in foods, agro-industrial and commodities, real estate and hotel, air transportation, banking and petrochemicals. The company also has investments in telecommunications and power generation and distribution. It also has a branded consumer foods business in China, ASEAN and an investment in a property development company in Singapore. The Group conducts businesses throughout the Philippines, around Metro Manila and in the regions of Luzon, Visayas and Mindanao.

J G SUMMIT HLDGS UNSP/ADR by JG Summit Holdings, Inc.

JG Summit Holdings Inc

These preliminary&nbsp;Third Quarter&nbsp;2024 revenue and Adjusted EBITDA results are within its previously announced&nbsp;guidance&nbsp;ranges.&nbsp;&nbsp;

News

Guidance

Forum Energy Technologies Reports Preliminary Q3 Revenue Of Approximately $208M (Est $214.5M), Bookings Of $205M

Federal Reserve Gov. Christopher J. Waller voiced concerns Monday over recent inflation data, signaling that the central bank must proceed cautiously <a href="https://www.benzinga.com/topic/interest-rates">on interest rate cuts. </a>
Speaking at a conference at Stanford University, Waller struck a slightly hawkish tone, highlighting the U.S. economy's strength while acknowledging worries over recent inflation upticks.
<h1 class="wp-block-heading">Solid Economic Growth but Disappointing Inflation</h1>
Waller emphasized the economy is on &#8220;solid footing,&#8221; with employment near the Federal Open Market Committee&#8217;s (FOMC) maximum objective. But he added, &#8220;The latest inflation data was disappointing.&#8221;
Despite progress in reducing inflation, recent figures suggest uneven progress toward the Fed&#8217;s 2% target.
Waller praised the economy&#8217;s resilience, noting that real GDP grew at a 2.2% annual rate in the first half of 2024 and is expected to accelerate in the third quarter. 
He also mentioned that household resources remain in good shape, though lower-income groups continue to face financial strain. &#8220;These revisions suggest that the economy is much stronger than previously thought, with little indication of a major slowdown in economic activity,&#8221; Waller said.
<h1 class="wp-block-heading">&#8216;Considerable Pent-Up Demand&#8217; As Interest Rates Fall</h1>
Waller highlighted continued strength in consumer spending, despite some moderation. 
Growth in personal consumption expenditures (PCE) has averaged around 2.5% this year. Waller&#8217;s business contacts expressed optimism about &#8220;considerable pent-up demand&#8221; for durable goods and home improvements, demand that has been delayed due to high interest rates.
As interest rates for credit cards and home equity loans begin to decline, Waller expects consumers to resume purchasing &#8220;durable goods, home improvements, and other big-ticket items.&#8221; 
&#8220;Now that rates have started to come down and are expected to come down more, consumers will be eager to make those purchases,&#8221; he said. 
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41314387/most-widely-hated-bull-market-reaches-2-year-milestone-top-20-s-p-500-stocks-drivin">&#8216;Most Widely Hated&#8217; Bull Market Reaches 2-Year Milestone: Top 20 S&amp;P 500 Stocks Driving The Rally</a>
<h1 class="wp-block-heading">Jobs Market Remains Quite Healthy</h1>
Waller also addressed the September jobs report, which far exceeded expectations. &#8220;The labor market remains quite healthy,&#8221; he said, pushing back against speculation that the Fed might have considered an emergency rate cut earlier in the summer. 
While Waller expects payroll gains to slow, he believes job growth will continue at a &#8220;solid rate.&#8221;
He did, however, caution that interpreting the October jobs report may be difficult due to temporary disruptions from recent hurricanes and the Boeing strike, which are expected to skew the numbers.
<h1 class="wp-block-heading">Inflation Rollercoaster and Rate Outlook</h1>
Turning to inflation, Waller expressed concern over September's likely increase in PCE inflation, the Fed's preferred measure. &#8220;We have made a lot of progress on inflation over the last year and a half, but that progress has clearly been uneven — at times it feels like being on a rollercoaster,&#8221; Waller said.
He remains uncertain whether the recent uptick in inflation is a temporary blip or a signal of more persistent inflationary pressures. &#8220;I will be watching the data carefully to see how persistent this recent uptick is,&#8221; he added.
Despite these concerns, Waller reaffirmed his outlook for gradual rate reductions over the next year, aligning with the FOMC&#8217;s median projection of 3.4% for the federal funds rate by the end of 2025. 
However, he acknowledged, &#8220;There is less certainty about the final destination.&#8221;
<h1 class="wp-block-heading">Market Reactions</h1>
Waller&#8217;s remarks have not significantly shifted interest-rate expectations. According to the CME FedWatch Tool, the odds of a 25-basis-point rate cut remained steady at 86%. 
However, if more Fed policymakers also express concerns about inflation in the days to come, and if Thursday's retail sales data exceeds expectations, the likelihood of the Fed holding rates unchanged could rise from here.
On Monday, Treasury yields were largely stable, with the two-year note yield — sensitive to rate policy — hovering around 4%. The U.S. dollar index (DXY), tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), rose 0.3%, reaching its highest level since late July.
Meanwhile, the S&amp;P 500 index, monitored via the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), gained 0.8% to close at 5,859 points, extending its record highs.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41319060/s-p-500-extends-record-highs-dow-breaks-43-000-ahead-of-pivotal-earnings-week-bitco">S&amp;P 500 Extends Record Highs, Dow Breaks 43,000 Ahead Of Pivotal Earnings Week, Bitcoin&#8217;s Rally Lifts Crypto Stocks: What&#8217;s Driving Markets Monday?</a></li>
</ul>

Macro Economic Events

Broad U.S. Equity ETFs

Currency ETFs

Econ #s

Economics

Federal Reserve

ETFs

PowerShares DB US Dollar Index Bullish Fund

Fed's Waller Signals Caution On Interest-Rate Cuts: 'Latest Inflation Data Was Disappointing'

Offerings

Forum Energy Technologies Reports Commencement Of Backstopped Private Offering Of $100M Of 5-year Senior Secured Bonds

<a href="https://www.forexlive.com/centralbank/feds-kashari-says-a-lot-of-progress-made-on-inflation-labor-market-is-strong-20241014/" title="https://www.forexlive.com/centralbank/feds-kashari-says-a-lot-of-progress-made-on-inflation-labor-market-is-strong-20241014/">https://www.forexlive.com/centralbank/feds-kashari-says-a-lot-of-progress-made-on-inflation-labor-market-is-strong-20241014/</a>

Fed's Kashkari Says We've Made A Lot Of Progress On Inflation, And Labor Market Is Strong; Not Worth It To Have Unemployment Rate Shoot Up; Don't Think China Is Remotely Competitive With U.S.; Not At All Worried That Yuan Could Replace Dollar As Global Reserve Currency; U.S. Competitive Position Is Very Very Strong, Though Can't Take It For Granted

INVO BioScience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) shares soared Monday after the company announced it closed <a href="https://www.benzinga.com/pressreleases/24/10/g41312767/invo-bioscience-and-naya-biosciences-close-merger-combined-company-to-operate-as-naya-biosciences-">its merger with NAYA Biosciences. </a>
The Details: Invo BioScience said the combined company will continue to operate its fertility business as well as expand its focus to the development of clinical-stage assets in oncology and autoimmune diseases. The company expects to change its name to Naya Biosciences and trade on the Nasdaq under the &#8220;NAYA&#8221; ticker.&nbsp;
The combined company will be led by Invo CEO Steve Shum, Invo CFO Andrea Goren and Dr. Daniel Teper, founder and former CEO of Naya Biosciences, who will be appointed as president of the combined company and CEO of the Naya Therapeutics subsidiary.&nbsp;
Read Next: <a href="https://www.benzinga.com/fintech/24/10/41295297/whats-going-on-with-sofi-technologies-stock">What&#8217;s Going On With SoFi Technologies Stock?</a>
&#8220;We are confident that our expanded portfolio business model and combined assets have the potential to create significant value for both legacy and new shareholders,&#8221; said Steve Shum, CEO of the combined company.
&#8220;Combining scalable, profitable revenues from our fertility business with the upside of innovative therapeutics optimizes risk-return for investors. In addition, the hub-and-spoke model allows for shared resources and talent to accelerate the development of our lean, agile subsidiaries," Shum said.&nbsp;
Invo shares climbed on heavy trading volume following Monday's announcement with more than 54 million shares traded in the session, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>.&nbsp;
INVO Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Invo BioScience shares are up 1.61% after-hours at $1.24 after gaining 92.55% in Monday&#8217;s regular session.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41277250/whats-going-on-with-first-solar-stock">What&#8217;s Going On With First Solar Stock?</a></li>
</ul>
Photo: Shutterstock&nbsp;

Health Care

Crowdsourcing

Movers

INVO

What Happened With Invo BioScience Stock Today?

Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) has outperformed the market over the past 15 years by 24.28% on an annualized basis producing an average annual return of 36.11%. Currently, Netflix has a market capitalization of $306.28 billion. 
Buying $100 In NFLX: If an investor had bought $100 of NFLX stock 15 years ago, it would be worth $10,022.09 today based on a price of $713.67 for NFLX at the time of writing.
<h3>Netflix's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728941426_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

NFLX

Here's How Much $100 Invested In Netflix 15 Years Ago Would Be Worth Today

EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) has outperformed the market over the past 20 years by 2.05% on an annualized basis producing an average annual return of 10.7%. Currently, EOG Resources has a market capitalization of $74.42 billion. 
Buying $1000 In EOG: If an investor had bought $1000 of EOG stock 20 years ago, it would be worth $7,702.94 today based on a price of $130.89 for EOG at the time of writing.
<h3>EOG Resources's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728941421_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $7,700 Today

ATEK

Athena Technology Acquisition Corp. II Says Financial Statements Contained Audit Opinion That Included Explanatory Paragraph Related To Ability To Continue As Going Concern

The text of the letter included:
Over much of the past two years, Medical Properties Trust has been the target of considerable scrutiny from short-selling hedge funds as well as certain media outlets.
In response to certain claims asserted by Viceroy Research, the Board&#39;s Audit Committee engaged Wachtell Lipton in early 2023 to conduct an independent investigation into the short-seller allegations, including with respect to MPT transactions involving Steward Healthcare beginning in 2016.
Wachtell Lipton in turn retained a leading global consulting firm to assist with financial forensics as part of this investigation. No limitations or restrictions were placed on the scope of the investigation and management cooperation with the investigation was exemplary.
The key findings from the investigation are as follows:
<ol>
<li>The investigation identified no evidence that MPT gratuitously overpays its operator-tenants for real estate.</li>
<li>The investigation identified no evidence of improper round-tripping.</li>
<li>The investigation found no evidence of improper recognition of &quot;uncollectable&quot; rent through GAAP-mandated straight-line revenue recognition. The investigation also found no evidence to substantiate the allegation that MPT was required to consolidate Steward&#39;s financial results.</li>
<li>The investigation concluded that neither Manolete Health nor MPT has an ownership interest in any Malta property or hospital.</li>
<li>The investigation yielded no evidence that management manipulated acquisitions or other metrics to meet compensation targets.</li>
<li>The investigation yielded no evidence of concerns regarding management integrity.</li>
</ol>

Medical Properties Trust Releases Letter To Shareholders Regarding Findings Of Independent, Forensic Investigation Into Short-seller Allegations; Says Board Continues To Stand Firmly Behind Its Management Team

Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) shares popped in afternoon trading Monday after Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) announced intentions to purchase power from <a href="https://www.benzinga.com/topic/nuclear-energy">small modular reactor (SMR) developer Kairos Power</a>.
What Happened: Google on Monday said it would purchase power from a fleet of SMRs made by Kairos as the company and other tech giants increasingly turn to nuclear for energy needs related to the <a href="http://benzinga.com/topic/ai">AI</a> revolution, per <a href="https://www.cnbc.com/2024/10/14/google-inks-deal-with-nuclear-company-as-data-center-power-demand-surges.html">CNBC</a>.
&#8220;We believe that nuclear energy has a critical role to play in supporting our clean growth and helping to deliver on the progress of AI,&#8221; Michael Terrell, senior director for energy and climate at Google, reportedly told reporters. 
&#8220;The grid needs these kinds of clean, reliable sources of energy that can support the build-out of these technologies,&#8221; Terrell said. &#8220;We feel like nuclear can play an important role in helping to meet our demand, and helping meet our demand cleanly, in a way that's more around the clock.&#8221;
Big tech companies are increasingly looking to nuclear power to meet the rising energy demands of data centers. Data centers need to have reliable power at all times and nuclear offers an emissions-free option. Many hyperscalers also have emissions-reduction goals that they are trying to meet.
Google plans to have its first reactor online by 2030, with more reactors expected to follow through 2035. 
"It is an incredibly promising bet, and one that, you know, if we can get these projects to scale and then scale globally, will deliver enormous benefits to communities and power grids around the world," Terrell said.
See Also: <a href="https://www.benzinga.com/news/24/10/41309060/nvidias-jensen-huang-says-chatgpt-led-to-awakening-of-ai-praises-sam-altmans-openai-as-one-of-most-c">Nvidia&#8217;s Jensen Huang Says ChatGPT Led To &#8216;Awakening Of AI,&#8217; Praises Sam Altman&#8217;s OpenAI As One Of Most Consequential Companies Of Our Time</a>
The Google news helped lift nuclear stocks across the board on Monday, but Oklo was among the biggest gainers. Investors may be speculating that Oklo could be one of the next companies to ink a deal with a big tech player, given the company&#8217;s ties to OpenAI and Sam Altman. 
Oklo went public in May through a merger with <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37906984/sam-altmans-under-the-radar-spac-fuses-ai-expertise-with-nuclear-energy-here-are-the-oth">AltC Acquisition Corp</a>, a special purpose acquisition company (SPAC) backed by Altman, who has also been the chair of Oklo&#8217;s board since 2015. Oklo is the only public company that Altman chairs.
Given Altman&#8217;s involvement with Oklo and OpenAI&#8217;s leadership in the AI space, it wouldn&#8217;t be surprising to see the companies work together in some capacity to meet rising energy demand. 
OpenAI&nbsp;recently <a href="https://www.benzinga.com/news/24/10/41149788/openai-valuation-soars-to-157b-in-latest-funding-round">secured new funding</a> at a valuation of $157 billion&nbsp;from investors including Nvidia, Microsoft, Thrive Capital, SoftBank and Ark Funds.
OKLO Price Action:&nbsp;<a href="http://benzinga.com/quote/oklo" target="_blank" rel="noreferrer noopener">Oklo shares</a>&nbsp;closed Monday up at 9.73%. The stock was up another 3.78% in after-hours, trading at $10.42, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of Oklo.

After-Hours Center

Tech

GOOG

GOOGL

OKLO

Sam Altman's Oklo Jumps On Google Nuclear Deal: What's Going On?

Arm Holdings PLC &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) has seen gains over the past week. Here&#8217;s <a href="https://www.benzinga.com/trading-ideas/technicals/24/10/41185402/arm-stock-softbanks-ai-goals-vs-bearish-market-trends">what you need to know.</a>
What To Know: The demand for semiconductors has grown, driven by advancements in artificial intelligence and mobile technology. Arm's technology is a critical component in devices such as smartphones and cloud services. Additionally, the partnership with Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) for the iPhone 16 may have also influenced investor confidence in the company.
Financially, Arm reported record revenue of $939 million for Fiscal year 2025, representing a 39% increase from the previous year. The gross margin stands at 96.5%, with licensing revenue growing by 72%. Currently, Arm is trading within a 52-week range of $46.50 to $188.75. The session volume reached 8.942 million shares, exceeding the 100-day average volume of 7.928 million shares.
The stock is also trending on social media such as Yahoo Finance and StockTwits, attracting increased investor attention and engagement.
ARM Price Action: Arm Holdings shares were up by 6.84% at $162.82 at market close Monday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="532" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14165055/ARM-1024x532.png" alt="" class="wp-image-594802" style="width:494px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14165055/ARM-1024x532.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14165055/ARM-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14165055/ARM-768x399.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14165055/ARM.png 1456w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/previews/24/10/41320620/unitedhealth-group-q3-earnings-preview-dow-jones-industrial-average-stock-could-move-marke">UnitedHealth Group Q3 Earnings Preview: Dow Jones Industrial Average Stock Could &#8216;Move Markets&#8217; Tuesday</a></li>
</ul>
Photo: Shutterstock.

AAPL

Arm Holdings Stock Climbs In A Week As Semiconductor Sector Strengthens

– Engineering Union Spokesperson

Management

Boeing To Send 60-Day Notices In Mid November To Staff Being Made Redundant As Part Of Sweeping Job Cuts

-- Reimbursement Determination for the PoNS Mouthpiece (HCPCS code A4594) set at $2,963.30 on Lump Sum Payment to be challenged by Helius -- &nbsp;
-- National Reimbursement Payment Determination from CMS for its PoNS Controller Deferred to the Next Cycle --
NEWTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Centers for Medicare &amp; Medicaid Services (CMS) posted final Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies fee schedule payment rates for the PoNS Mouthpiece (HCPCS code A4594) at $2,963.30 to be implemented January 1, 2025 and deferred final national determination of the payment rate for the PoNS Controller (HCPCS Code A4593) to the next payment cycle.

HSDT

Helius Medical Technologies Announces Reimbursement Determination For PoNs Mouthpiece Set At $2,963.30 On Lump Sum Payment To Be Challenged By Co; Disagrees With CMS' Methods, Pricing & Deferral For Determining Payment Rates For PoNs Mouthpiece & Pons Controller

Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $128.22, a high estimate of $143.00, and a low estimate of $120.00. Marking an increase of 4.61%, the current average surpasses the previous average price target of $122.57. 
<img src="https://www.benzinga.com/files/images/story/2024/1728939648_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Abbott Laboratories among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$129.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$124.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Raj Denhoy</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Hold</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$131.00</td>
<td>-</td>
</tr>
<tr>
<td>Raj Denhoy</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Joanna Wiensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$143.00</td>
<td>$140.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Abbott Laboratories. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Abbott Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Abbott Laboratories's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Abbott Laboratories's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ABT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Abbott Laboratories analyst ratings.</a>
<h2>Discovering Abbott Laboratories: A Closer Look</h2>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
<h3>Key Indicators: Abbott Laboratories's Financial Health</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Abbott Laboratories showcased positive performance, achieving a revenue growth rate of 4.0% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Abbott Laboratories's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 12.55%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Abbott Laboratories's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.33% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Abbott Laboratories's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.79%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.38, Abbott Laboratories adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Beyond The Numbers: 9 Analysts Discuss Abbott Laboratories Stock

In the last three months, 5 analysts have published ratings on Betterware de Mexico SAPI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.5, with a high estimate of $22.50 and a low estimate of $22.50. This current average has not changed from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1728939642_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Betterware de Mexico SAPI. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Betterware de Mexico SAPI. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Betterware de Mexico SAPI compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Betterware de Mexico SAPI's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Betterware de Mexico SAPI's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BWMX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Betterware de Mexico SAPI analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Betterware de Mexico SAPI</h2>
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided into different categories based on the type of products it sells and includes, kitchen and food preservation, home solutions, bathroom, laundry &amp; cleaning, tech and mobility, and bedroom and wellness products. The JAFRA's segment is divided into fragrance, color, skincare, and toiletries products. The company generates a majority of its revenue from the Beauty and personal care (B&amp;PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.
<h3>Betterware de Mexico SAPI's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Betterware de Mexico SAPI showcased positive performance, achieving a revenue growth rate of 5.26% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Betterware de Mexico SAPI's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.87% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 19.61%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.75%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 3.46, Betterware de Mexico SAPI adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BWMX

Assessing Betterware de Mexico SAPI: Insights From 5 Financial Analysts

Across the recent three months, 9 analysts have shared their insights on iRhythm Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $110.67, a high estimate of $145.00, and a low estimate of $78.00. A 16.79% drop is evident in the current average compared to the previous average price target of $133.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1728939633_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of iRhythm Technologies by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$78.00</td>
<td>-</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Allen Gong</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$117.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$119.00</td>
<td>$138.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to iRhythm Technologies. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of iRhythm Technologies compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of iRhythm Technologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into iRhythm Technologies's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IRTC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on iRhythm Technologies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind iRhythm Technologies</h2>
iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The company's portfolio includes ambulatory cardiac monitoring services on a platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for several days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company derived its revenue from the United States.
<h3>Breaking Down iRhythm Technologies's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: iRhythm Technologies displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 19.27%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: iRhythm Technologies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -13.58% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): iRhythm Technologies's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -21.22%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): iRhythm Technologies's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.2%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 7.43, iRhythm Technologies faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IRTC

Beyond The Numbers: 9 Analysts Discuss iRhythm Technologies Stock

Across the recent three months, 7 analysts have shared their insights on Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $80.43, with a high estimate of $93.00 and a low estimate of $77.00. This upward trend is evident, with the current average reflecting a 6.43% increase from the previous average price target of $75.57.
<img src="https://www.benzinga.com/files/images/story/2024/1728939625_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Globus Medical among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$77.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$79.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Globus Medical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Globus Medical compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Globus Medical's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Globus Medical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GMED/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Globus Medical analyst ratings.</a>
<h2>Get to Know Globus Medical Better</h2>
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.
<h3>Breaking Down Globus Medical's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Globus Medical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 115.93% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Globus Medical's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 5.04%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Globus Medical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.8%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.64%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Globus Medical's debt-to-equity ratio is below the industry average. With a ratio of 0.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GMED

The Analyst Verdict: Globus Medical In The Eyes Of 7 Experts

Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) is preparing to release its quarterly earnings on Tuesday, 2024-10-15. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Bank of America to report an earnings per share (EPS) of $0.77.
Anticipation surrounds Bank of America's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company beat EPS by $0.03, leading to a 0.34% drop in the share price the following trading session.
Here's a look at Bank of America's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.80</td>
<td>0.77</td>
<td>0.63</td>
<td>0.81</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.83</td>
<td>0.83</td>
<td>0.70</td>
<td>0.90</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>2.0%</td>
<td>-1.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1728939618_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Bank of America were trading at $41.95 as of October 11. Over the last 52-week period, shares are up 51.74%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/BAC/earnings">To track all earnings releases for Bank of America visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

A Glimpse of Bank of America's Earnings Potential

Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) has outperformed the market over the past 5 years by 19.96% on an annualized basis producing an average annual return of 34.38%. Currently, Wingstop has a market capitalization of $11.69 billion. 
Buying $100 In WING: If an investor had bought $100 of WING stock 5 years ago, it would be worth $438.32 today based on a price of $399.05 for WING at the time of writing.
<h3>Wingstop's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728939617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WING

$100 Invested In Wingstop 5 Years Ago Would Be Worth This Much Today

During the last three months, 13 analysts shared their evaluations of AvidXchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDX#NASDAQ">AVDX</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $10.23, a high estimate of $14.00, and a low estimate of $7.00. Highlighting a 22.79% decrease, the current average has fallen from the previous average price target of $13.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1728939617_0_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of AvidXchange Holdings by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Dominick Gabriele</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Neutral</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Josh Beck</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$9.00</td>
<td>$11.50</td>
</tr>
<tr>
<td>Rufus Hone</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$11.00</td>
<td>$13.50</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Timothy Chiodo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>David Koning</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to AvidXchange Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AvidXchange Holdings compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of AvidXchange Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of AvidXchange Holdings's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AVDX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AvidXchange Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind AvidXchange Holdings</h2>
AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.
<h3>Unraveling the Financial Story of AvidXchange Holdings</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, AvidXchange Holdings showcased positive performance, achieving a revenue growth rate of 15.33% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: AvidXchange Holdings's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 0.41%, the company may face hurdles in effective cost management.
Return on Equity (ROE): AvidXchange Holdings's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.06%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): AvidXchange Holdings's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.02%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: AvidXchange Holdings's debt-to-equity ratio is below the industry average at 0.21, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

JG Summit Holdings

JG Summit Holdings (JGSMY) Forecast

JG Summit Holdings (OTC:JGSMY) Stock, Quote.Headers.trade-ideas